DDInter1956 DDInter183
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) downregulates {v} (Gene) HSPA1A
HSPA1A {u} (Gene) is upregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) downregulates {v} (Gene) HSPA1A
HSPA1A {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secnidazole
Secnidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) upregulates {v} (Gene) ANO10
ANO10 {u} (Gene) is downregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is upregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) upregulates ANO10 (Gene) and ANO10 (Gene) is downregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Zalcitabine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole